Methods and compositions to regulate mapt splicing for modeling and treatment of tauopathies
AssigneeThe Trustees of Columbia University in the City of New York
InventorsYocelyn RECINOS, Chaolin ZHANG
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorsYocelyn RECINOS, Chaolin ZHANG
Estimating the term…
Compounds for, and methods of, modeling and treating a neurodegenerative disease, including without limitation frontal temporal dementia (FTD), are provided. An effective dose of a pharmaceutical composition is administered to a patient in need thereof, where the pharmaceutical composition targets at least one muscleblind-like protein (MBNL) binding site on exon 10 of microtubule-associated protein tau (MAPT) to block MBNL binding thereto. The at least one MBNL binding site may be 2 binding sites. The pharmaceutical composition may include the nuclease-inactive dCas13d in complex, with one or more guide RNAs, and/or antisense oligonucleotides (ASOs).
A composition for treating a neurodegenerative disease, the composition comprising at least one component that targets at least one muscleblind-like protein (MBNL) binding site near exon 10 of microtubule-associated protein tau (MAPT) to block MBNL binding thereto and modulate exon 10 splicing.
A method of treating a neurodegenerative disease comprising the step of administering to a patient in need thereof an effective dose of a pharmaceutical composition which targets at least one muscleblind-like protein (MBNL) binding site near exon 10 of microtubule-associated protein tau (MAPT) to block MBNL binding thereto and modulate exon 10 splicing.
A method of expressing adult MAPT splice isoforms in human cells, the method comprising over expressing MBNL proteins in the human cells.
Dependencies are inferred from the claim text.